Cyclerion Therapeutics (NASDAQ:CYCN) Issues Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) issued its quarterly earnings results on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.19, FiscalAI reports. The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.10 million. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.

Cyclerion Therapeutics Price Performance

CYCN stock opened at $1.55 on Wednesday. The stock has a market capitalization of $6.09 million, a PE ratio of -2.07 and a beta of 0.94. The company’s 50-day moving average is $1.38 and its 200-day moving average is $1.68. Cyclerion Therapeutics has a 1 year low of $1.03 and a 1 year high of $3.79.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent filing with the SEC. 75.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.